Investment Thesis
Lucid Diagnostics is an early-stage medtech company with minimal revenue ($1.3M) and unsustainable operating losses (-$12.1M), generating deeply negative free cash flow (-$12.3M). Despite a $27.9M cash position, the company faces severe financial distress with a 6.07x debt-to-equity ratio and approximately 2+ years of cash runway at current burn rates, requiring dramatic revenue acceleration or capital restructuring to survive.
Strengths
- Positive gross margin of 30% demonstrates viable product-level economics if scaled
- Substantial cash position of $27.9M provides operational runway for development and commercialization
- Revenue growing 8.3% YoY indicates early commercial momentum in market adoption
Risks
- Operating losses of -$12.1M dwarf $1.3M revenue; no discernible path to profitability or operating break-even
- Negative free cash flow of -$12.3M combined with 6.07x debt-to-equity ratio creates severe financial distress; limited ability to service debt or fund operations beyond cash reserves
- Current burn rate and revenue scale suggest company exhausts cash within 2+ years absent major revenue inflection or capital raise; negative interest coverage (-757x) indicates insolvency risk
Key Metrics to Watch
- Quarterly revenue growth rate and timeline to operating expense neutrality
- Monthly cash burn rate and runway in months remaining
- Debt refinancing requirements and near-term covenant compliance
Financial Metrics
Revenue
1.3M
Net Income
-13.9M
EPS (Diluted)
$-0.59
Free Cash Flow
-12.3M
Total Assets
34.1M
Cash
27.9M
Profitability Ratios
Gross Margin
30.0%
Operating Margin
-964.5%
Net Margin
-1,107.4%
ROE
-347.7%
ROA
-40.8%
FCF Margin
-980.6%
Balance Sheet & Liquidity
Current Ratio
1.07x
Quick Ratio
1.05x
Debt/Equity
6.07x
Debt/Assets
88.3%
Interest Coverage
-757.13x
Long-term Debt
24.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:43:17.507702 |
Data as of: 2026-03-31 |
Powered by Claude AI